The COLGALT1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Raji human B lymphocyte line, designed to disrupt the COLGALT1 gene. This product provides a heterogeneous pool of edited cells for investigating loss-of-function effects of COLGALT1, which encodes a galactosyltransferase that initiates collagen glycosylation by transferring galactose to hydroxylysine residues. The polyclonal format enables robust functional screening without the requirement for single-cell cloning, preserving population-level heterogeneity and facilitating studies of gene function in a context that more closely mirrors physiological diversity. It is an ideal tool for researchers examining the role of COLGALT1 in post-translational modification, extracellular matrix biology, and disease-related pathways.
Raji cells are an immortalized B lymphocyte line derived from a human Burkitt lymphoma, widely used as a model system in immunology, oncology, and cell signaling research. These suspension cells exhibit characteristics of mature B cells, including expression of surface immunoglobulins and receptors involved in antigen presentation and immune synapse formation. Their rapid proliferation and well-characterized signaling networks make them suitable for CRISPR-based gene editing applications. The Raji background offers a unique platform to explore how COLGALT1-mediated collagen glycosylation influences B cell behavior, particularly in the context of tumor microenvironment interactions and lymphoid tissue organization.
COLGALT1 functions downstream of transcriptional regulators of collagen synthesis and ER stress pathways, catalyzing the addition of galactose to hydroxylysine residues on collagen types I, II, and III. It interacts with prolyl hydroxylase and lysyl hydroxylase, forming complexes that coordinate collagen folding, stability, and secretion. The resulting glycosylated collagen is a key component of the extracellular matrix, contributing to tissue architecture and integrin-mediated signaling. Disruption of COLGALT1 abolishes this galactosylation step, impairing collagen stability and ECM assembly, and potentially affecting downstream targets such as other ECM components and cell adhesion receptors.
In the Raji B lymphocyte model, COLGALT1 knockout may alter cell adhesion and microenvironment interactions, as collagen glycosylation influences ECM-integrin crosstalk and cell migration. Although B cells are not classical collagen-producing cells, they reside within collagen-rich niches and rely on ECM interactions for homing, activation, and survival. Loss of COLGALT1 function could therefore perturb B cell dynamics within lymphoid tissues and tumor microenvironments, providing insights into connective tissue disorder mechanisms, including osteogenesis imperfecta type XIII. This model bridges the gap between basic collagen biology and immune cell behavior.
Key research applications include the study of collagen glycosylation dynamics, extracellular matrix organization, and modeling of connective tissue diseases. Representative assays such as Western blotting for collagen glycosylation status, immunofluorescence for ECM deposition, collagen secretion assays, and RT-qPCR for collagen-related gene expression can be employed. Additionally, this knockout model is valuable for investigating B cell adhesion, migration, and tumor microenvironment crosstalk. For further technical specifications, pricing, and ordering details, please contact Ascent Research.
